Comparison of the pharmacodynamic profiles of a biosimilar filgrastim and Amgen filgrastim: results from a randomized, phase I trial.

Waller CF, Bronchud M, Mair S, Challand R

Open source

DOI
10.1007/s00277-010-0973-6
Published
2010 Oct
Container
Annals of hematology
Publisher
Not recorded
Open access
yes

Credibility signals

limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

Cite this work

BibTeX

@article{allodium:10.1007/s00277-010-0973-6,
  title = {Comparison of the pharmacodynamic profiles of a biosimilar filgrastim and Amgen filgrastim: results from a randomized, phase I trial.},
  author = {Waller CF and Bronchud M and Mair S and Challand R},
  year = {2010},
  journal = {Annals of hematology},
  doi = {10.1007/s00277-010-0973-6},
  url = {https://doi.org/10.1007/s00277-010-0973-6}
}

RIS

TY  - JOUR
TI  - Comparison of the pharmacodynamic profiles of a biosimilar filgrastim and Amgen filgrastim: results from a randomized, phase I trial.
AU  - Waller CF
AU  - Bronchud M
AU  - Mair S
AU  - Challand R
PY  - 2010
JO  - Annals of hematology
DO  - 10.1007/s00277-010-0973-6
UR  - https://doi.org/10.1007/s00277-010-0973-6
ER  - 

APA

CF, W., M, B., S, M., & R, C. (2010). Comparison of the pharmacodynamic profiles of a biosimilar filgrastim and Amgen filgrastim: results from a randomized, phase I trial.. Annals of hematology. https://doi.org/10.1007/s00277-010-0973-6

Source records